FDA approves Opdivo for metastatic non-squamous NSCLC
12 October 2015 | By Victoria White
In a Phase 3 trial, Opdivo demonstrated superior overall survival (OS) in previously treated metastatic non-squamous NSCLC compared to chemotherapy...
List view / Grid view
News
SMC accepts six new medicines for use by NHS Scotland
12 October 2015 | By Victoria White
The medicines accepted by the SMC include Herceptin for stomach cancer, radium 223 (Xofigo) and abiraterone (Zytiga) for prostate cancer, and nintedanib (Ofev) for idiopathic pulmonary fibrosis
Black Swan Analysis shortlisted for Growing Business Award
12 October 2015 | By Black Swan Analysis
Black Swan Analysis has been shortlisted as the 'Micro Business of the Year' for the 2015 Growing Business Awards...
Data show denosumab achieves greater bone mineral density gains
12 October 2015 | By Victoria White
Results from a Phase 4 study show that denosumab achieved greater gains in bone mineral density than zoledronic acid in postmenopausal women with osteoporosis...
Cosentyx demonstrates sustained efficacy in plaque psoriasis
12 October 2015 | By Victoria White
Cosentyx is the first fully human interleukin-17A (IL-17A) inhibitor approved in Europe and the US to treat adult moderate-to-severe plaque psoriasis...
Lilly acquires rights to hypoglycaemia rescue treatment
12 October 2015 | By Victoria White
Intranasal glucagon, currently in Phase III trials, uses a glucagon nasal powder formulation that is delivered in an emergency situation...
#CPhIChat returns to CPhI Worldwide for the second successive year
9 October 2015 | By Victoria White
#CPhIChat is an industry-wide Tweetchat for pharma professionals working across the supply chain, aimed to stimulate conversations on key industry issues...
Another NICE recommendation for melanoma drug Keytruda
9 October 2015 | By Victoria White
This new recommendation for Keytruda is for treating advanced melanoma that has not been previously treated with ipilimumab...
Verastem reduces its workforce by 50%
9 October 2015 | By Victoria White
Verastem’s announcement comes just weeks after the company had to abandon enrolment in a Phase 2 study of its lead cancer drug VS-6063...
Eltrombopag shown to be effective in children with ITP
9 October 2015 | By Victoria White
The study demonstrate that eltrombopag is well tolerated and effective, consistently stabilising the platelet count to over 50 X 109 per litre within 2-6 weeks for 40% of children...
Ocrelizumab signficantly reduces disability progression in MS in studies
9 October 2015 | By Victoria White
Roche’s Chief Medical Officer said the results of the pivotal trials have the potential to transform the treatment of MS...
BI 655066 cleared skin better than ustekinumab in psoriasis study
8 October 2015 | By Victoria White
Boehringer Ingelheim has reported new results from a Phase II head-to-head psoriasis study that showed superior efficacy of the company’s biologic compound BI 655066 over ustekinumab...
FDA grants Fast Track designation to avelumab for Merkel cell carcinoma
8 October 2015 | By Victoria White
The designation relates to the clinical development programme for avelumab in metastatic MCC, which includes the Phase II study, JAVELIN Merkel 200...
Abemaciclib gets Breakthrough Therapy Designation
8 October 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation to abemaciclib for patients with refractory HR+ advanced or metastatic breast cancer...
Lemtrada treatment effects maintained over five years in RRMS
8 October 2015 | By Victoria White
Lemtrada targets CD52, a protein abundant on T and B cells. Circulating T and B cells are thought to be responsible for the damaging inflammatory process in MS...
